Hemab Therapeutics Reports Q1 GAAP EPS of -$23.98
Hemab Therapeutics (NASDAQ: COAG) reported a first-quarter GAAP earnings per share loss of $23.98, reflecting significant financial pressure amid ongoing operations. The company's cash and equivalents stood at $163.5 million as of March 31, down from $185.5 million in December.
Topics: biotech financials ipo